Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,611.13
(
-0.20%
)
US TECH 100
23,588.00
(
-0.87%
)
Dow Jones
46,084.46
(
-0.30%
)
Brent Oil
103.34
(
-3.04%
)
Bitcoin
69,968.18
(
-1.77%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: flatlander_60048 post# 97783

Tuesday, 09/27/2011 12:46:22 PM

Tuesday, September 27, 2011 12:46:22 PM

Post# of 257259
NVS submits MAA for NVA237 (a/k/a Seebri Breezhaler) for COPD:

http://finance.yahoo.com/news/NVA237-Filed-in-Europe-and-prnews-3474119034.html?x=0&.v=1

NVS also presented new phase-3 data for this drug today at the ERS conference.

See the prologue of #msg-64761738 for background info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now